BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12519351)

  • 21. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China.
    Tanaka M; Zhang YX; Ishida H; Akasaka T; Sato K; Hayakawa I
    J Med Microbiol; 1995 Mar; 42(3):214-9. PubMed ID: 7884804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
    Couzinet S; Yugueros J; Barras C; Visomblin N; Francois P; Lacroix B; Vernet G; Lew D; Troesch A; Schrenzel J; Jay C
    J Microbiol Methods; 2005 Feb; 60(2):275-9. PubMed ID: 15590102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
    Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
    Watanabe S; Ito T; Hiramatsu K
    J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones.
    Guirao GY; Martínez Toldos MC; Mora Peris B; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    J Antimicrob Chemother; 2001 Feb; 47(2):157-61. PubMed ID: 11157899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation between methicillin-resistance and resistance to fluoroquinolones in Staphylococcus aureus and Staphylococcus epidermidis].
    Cafiso V; Campanile F; Borbone S; Caia A; Cascone C; Santagati M; Stefani S
    Infez Med; 2001 Jun; 9(2):90-7. PubMed ID: 12698021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates.
    Kim MJ; Yun HJ; Kang JW; Kim S; Kwak JH; Choi EC
    J Antimicrob Chemother; 2003 Apr; 51(4):1011-6. PubMed ID: 12654771
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
    Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
    Yamakawa T; Mitsuyama J; Hayashi K
    J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
    Linde HJ; Schmidt M; Fuchs E; Reischl U; Niller HH; Lehn N
    Antimicrob Agents Chemother; 2001 May; 45(5):1553-7. PubMed ID: 11302827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.